Pilot Study of the Combination of Melphalan, Carboplatin and Etoposide as a Conditioning Regimen for Relapsed Lymphoma Patients
Auro del Giglio(Faculdade de Medicina do ABC), Carlos Sampaio, Luciano J. Costa(University of Alabama at Birmingham), Hélio Pinczowski(Apple (Israel)), P. Neves(Samaritan Hospital), Augusto César de Andrade Mota(Santa Casa Hospital), P. Boente, Paulo César Spotti Varella, J.R. Luzzi(Samaritan Hospital)
Cited by 5
Related Papers
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484